

[Mesna](#)

Not recommended as an essential medicine

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.5. Supportive medicines](#)

ATC codes: [V03AF01](#)

Indication

Unspecified malignant neoplasms of ill-defined or unspecified sites ICD11 code: [2D9Z](#)

INN

Mesna

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg ; 600 mg

EML status history

First added in 2009 ([TRS 958](#))

Removed in 2015 ([TRS 994](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Mesna](#)

DrugBank

[Mesna \(Coenzyme M\)](#)

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of mesna was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for mesna for more information.